-
ONC212
Brincidofovir (BCV) is an oral antiviral being developed for the treatment of smallpox under the U.S. Food and Drug Administration’s Animal Efficacy Rule, which allows for testing of investigational drugs in animal models to support effectiveness in diseases that are not ethical or feasible to study in humans.
-
ONC206
Brincidofovir (BCV) is an oral antiviral being developed for the treatment of smallpox under the U.S. Food and Drug Administration’s Animal Efficacy Rule, which allows for testing of investigational drugs in animal models to support effectiveness in diseases that are not ethical or feasible to study in humans.
-
ONC201
Brincidofovir (BCV) is an oral antiviral being developed for the treatment of smallpox under the U.S. Food and Drug Administration’s Animal Efficacy Rule, which allows for testing of investigational drugs in animal models to support effectiveness in diseases that are not ethical or feasible to study in humans.
-
Forward Looking
This website includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties, and other factors, including the possibility that the FDA and other regulatory authorities may not approve brincidofovir or brincidofovir-based regimens in the currently anticipated timelines or at all, and marketing approvals, if granted, may have significant limitations on their use.
-
Expanded Access
As of May 9, 2019, Chimerix discontinued clinical trials of brincidofovir (BCV) for the treatment of adenovirus infections. We made the existing clinical supply of oral BCV available to patients with serious adenovirus or orthopoxvirus infections as part of the expanded access program.
-
Tembexa
Brincidofovir (BCV) is an oral antiviral being developed for the treatment of smallpox under the U.S. Food and Drug Administration’s Animal Efficacy Rule, which allows for testing of investigational drugs in animal models to support effectiveness in diseases that are not ethical or feasible to study in humans.
-
Biodefense
Chimerix is committed to completing development of a new antiviral therapy to treat smallpox in the event of an accidental outbreak or bioterror attack.